title: Intravitreal adalimumab for refractory uveitis-related macular edema.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of intravitreal adalimumab injections on refractory cystoid macular edema (CME) secondary to noninfectious uveitis.
  
  
  METHODS
  Prospective, noncomparative, interventional case series.
  
  
  METHODS
  Eight consecutive patients with controlled uveitis and chronic, refractory CME who had failed steroid treatment.
  
  
  METHODS
  Intravitreal adalimumab injections were given monthly for 3 months.
  
  
  METHODS
  Mean change in central retinal thickness (CRT) on optical coherence tomography (OCT); secondary objective was the mean change in best-corrected visual acuity (BCVA).
  
  
  RESULTS
  Five of the eight patients completed the 6-month follow-up. For all 5 patients, the changes in BCVA from baseline to 3 months were not statistically significant (P=0.070). Similarly, the change in BCVA from baseline to 6 months was not statistically significant (P=1.0). The mean CRT at baseline was 692 microm. The changes from baseline to 3 months were not statistically significant (P=0.466); the changes from baseline to 6 months were also not statistically significant (P=0.808). We did not observe any ocular or systemic adverse effects.
  
  
  CONCLUSIONS
  Intravitreal adalimumab showed no efficacy in improving BCVA or reducing CRT in patients with chronic uveitic macular edema.
authors.affiliation: Department of Ophthalmology, Aristotle University, Thessaloniki, Greece. androudi@otenet.gr
authors.forename: Sofia
authors.initials: S
authors.lastname: Androudi
authors.forename: Evangelia
authors.initials: E
authors.lastname: Tsironi
authors.forename: Christos
authors.initials: C
authors.lastname: Kalogeropoulos
authors.forename: Athina
authors.initials: A
authors.lastname: Theodoridou
authors.forename: Periklis
authors.initials: P
authors.lastname: Brazitikos
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012160:Retina / Q000187:drug effects; D019233:Retreatment; D041623:Tomography, Optical Coherence; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014605:Uveitis / Q000150:complications / Q000188:drug therapy*; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab